Effect of Age at the Start of Iron Chelation Therapy on Gonadal Function in β-Thalassemia Major
Open Access
- 13 September 1990
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 323 (11) , 713-719
- https://doi.org/10.1056/nejm199009133231104
Abstract
Patients with transfusion-dependent thalassemia major tend to have abnormal growth and sexual maturation at puberty, presumably as a result of pituitary iron overload. This study was designed to determine whether chelation therapy with deferoxamine before the age of puberty would ameliorate this problem.This publication has 34 references indexed in Scilit:
- A Prospective Evaluation of Iron Chelation Therapy in Children With Severe β-ThalassemiaAmerican Journal of Diseases of Children, 1988
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985
- Editorial RetrospectiveNew England Journal of Medicine, 1983
- Survival and desferrioxamine in thalassaemia major.BMJ, 1982
- Gonadotropin Insufficiency in Patients with Thalassemia Major*Journal of Clinical Endocrinology & Metabolism, 1979
- Endocrine Abnormalities in Thalassemia MajorAmerican Journal of Diseases of Children, 1979
- GONADOTROPHIN, THYROTROPHIN AND PROLACTIN RESERVE IN β THALASSAEMIAClinical Endocrinology, 1978
- ENDOCRINE FUNCTION IN THALASSEMIA MAJORAnnals of the New York Academy of Sciences, 1974
- Growth of Children with Thalassaemia: Effect of Different Transfusion RegimensArchives of Disease in Childhood, 1970
- Endocrine Function in Thalassemia MajorJournal of Clinical Endocrinology & Metabolism, 1968